It garnered approval from the United States Food and Drug Administration (FDA) in August 2024 for the treatment of adult and pediatric patients aged 12 years and older diagnosed with World Health Organization (WHO) grade 2 astrocytoma or oligodendroglioma harboring IDH mutations (2). This evidence concerns the gene IDH1 and oligodendroglioma.